A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 May 2017
At a glance
- Drugs Baricitinib (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 11 May 2017 Status changed from recruiting to active, no longer recruiting.
- 03 May 2017 Planned End Date changed from 1 Oct 2017 to 1 Nov 2017.
- 17 May 2016 Planned End Date changed from 1 Jan 2018 to 1 Oct 2017.